Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Halting Hallucinations: A Discussion of Management Strategies for Parkinson’s Disease Psychosis

Listen as Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, discuss clinical strategies for diagnosing and managing Parkinson’s disease psychosis.
Marwan Sabbagh, MD, FAAN
Marta San Luciano, MD, MS, FAAN
Released: November 15, 2022

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.

Information on this Educational Activity

Faculty

Marwan Sabbagh, MD, FAAN

Professor of Neurology
Alzheimer's and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Marwan Sabbagh, MD, FAAN: consultant/advisor/speaker: Alzheon, Biogen, Eisai, Genentech-Roche, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Signant Health, Synaptogenix, T3D; ownership interest (stocks/stock options): Athira, Cortexyme/Quince Therapeutics, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Seq BioMarque, TransDermix, uMethod Health, Versanum; royalties or patent beneficiary: Humanix.
Marta San Luciano, MD, MS, FAAN

Associate Professor of Neurology
University of California, San Francisco
Attending Neurologist
Neurology/Movement Disorders and Neuromodulation Center
University of California, San Francisco Medical Center
San Francisco, California

Marta San Luciano, MD, MS, FAAN, has no relevant financial relationships to disclose.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Acadia Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings